Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia 7Leukemia, Myeloid, Acute 5Glioblastoma 5Gliosarcoma 4Congenital Abnormalities 4Colorectal Neoplasms 4Wilms Tumor 3Lung Neoplasms 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Erythroblastic, Acute 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Sarcoma 2Rectal Neoplasms 2Precancerous Conditions 2Myelodysplastic Syndromes 2Kidney Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Brain Neoplasms 2Anemia, Refractory, with Excess of Blasts 2Thrombocytopenia 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Squamous Intraepithelial Lesions 1Ovarian Neoplasms 1Oligodendroglioma 1

Interventions

Transcranial Direct Current Stimulation 1Modafinil 1Mental Status and Dementia Tests 1Lomustine 1Exercise 1Donepezil 1DNA Methylation 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cognition Disorders × DNA Methylation × Clear all
NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
592 enrolled
CNS

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡